Business Context and Reporting Period
This Form 8-K Current Report was filed by NanoVibronix, Inc. on October 13, 2016 (with events reported through October 19, 2016). The filing details significant changes to the Company's executive leadership and Board of Directors, including the appointment of a new Chief Executive Officer (CEO) and Chairman of the Board, and the resignation of the former CEO.
Key Financial Metrics and Compensation
The filing does not contain financial performance data such as revenue, profit, cash flow, or debt levels. It focuses exclusively on executive compensation arrangements and equity grants:
- Christopher M. Fashek (New Chairman/Director): Granted a stock option for 91,679 shares at an exercise price of $5.50. Annual cash compensation is $100,000, plus a potential one-time $25,000 bonus if the stock lists on a national exchange within six months.
- Brian M. Murphy (New CEO/Director): Base salary of $181,000, with automatic increases to $200,000 and $225,000 upon reaching gross sales milestones of $1 million and $2 million, respectively. Eligible for an annual performance bonus up to $150,000 (2017) or $100,000 (subsequent years). Eligible for a one-time $75,000 bonus upon stock listing within six months.
- William Stern (Former CEO, New President/Vice Chairman): Granted stock options for 35,000 shares at an exercise price of $5.55.
Material Changes Versus Prior Period
The primary material change is the restructuring of the Company's top management team effective October 13, 2016:
- Leadership Transition: William Stern resigned as CEO and was appointed President and Vice Chairman of the Board. Brian M. Murphy was appointed CEO and Director.
- Board Composition: Christopher M. Fashek was appointed Director and Chairman of the Board.
- Compensation Structure: New employment agreements and stock option plans were established for the incoming leadership, introducing performance-based salary escalators and listing bonuses.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The appointment of Brian M. Murphy highlights a strategic focus on commercial growth, leveraging his 25+ years of experience in medical devices and sales operations. The compensation packages include specific incentives tied to achieving gross sales milestones ($1M and $2M) and listing the Company's stock on a registered national securities exchange within six months.
Risks and Contingencies:
- Retention and Vesting: Equity grants for Mr. Fashek and Mr. Stern include accelerated vesting provisions in the event of a change in control or failure to nominate/re-elect the director.
- Severance Obligations: Mr. Murphy's employment agreement includes significant severance provisions (12 months' salary plus target bonus) if terminated without cause or if he resigns for good reason.
- Operational Milestones: Future cash compensation for the CEO is contingent on the Company generating specific levels of gross sales.
Key Facts for Investor Verification
- Verify the Company's current gross sales figures to assess the likelihood of triggering the CEO's salary increases and performance bonuses.
- Confirm the status of the Company's efforts to list its Common Stock on a registered national securities exchange within the six-month window specified in the bonus agreements.
- Review the full text of the attached Exhibits (10.1, 10.2, 10.3) for detailed terms regarding non-compete clauses, change-in-control definitions, and specific vesting schedules.
- Monitor the Company's cash position to ensure it can meet the new annual cash compensation obligations ($100,000 for Chairman, $181,000+ for CEO) and potential severance liabilities.